Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist developed as a long-acting analogue of the endogenous incretin hormone GLP-1. It shares approximately 94% structural homology with native GLP-1 but incorporates key modifications — including a C18 fatty diacid chain attached via a linker to lysine at position 34 — which confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation and extend its plasma half-life significantly compared to endogenous GLP-1.
In preclinical research models, semaglutide has been extensively studied for its ability to stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and reduce food intake via central hypothalamic pathways. These properties make it a highly valuable tool in metabolic disease research, particularly in the study of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
Emerging research also investigates semaglutide’s potential neuroprotective and cardioprotective mechanisms, with studies exploring its influence on inflammatory pathways and oxidative stress markers.
Store at -20°C, protected from light and moisture. Reconstitute in bacteriostatic water or sterile PBS prior to use.
Molecular Formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight
4113.6 g/mol
Purity
>98%
CAS Number
910463-68-2
Form
Lyophilised Powder
Research Applications
Metabolic disease research, Type 2 diabetes models, Obesity and appetite regulation, Cardiovascular research, Neuroprotection studies, NASH and hepatic lipid metabolism
For research purposes only. Not for human use.
Reviews
There are no reviews yet.